All In Biotech

NDA 021881 · Salix Pharms

Moviprep

Ascorbic Acid, Polyethylene Glycol 3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, Sodium Sulfate · Oral

Last checked: Nov 20, 2026Latest source record: Apr 6, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Aug 2, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

617

128 Phase 3, 49 recruiting

FAERS reports

2,319

1,888 serious, 254 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2025.

MoviPrep® is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. MoviPrep is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. ( 1 )

Mechanism: The primary mode of action is osmotic action of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MOVIPREP · ASCORBIC ACID 4.7GM; POLYETHYLENE GLYCOL 3350 100GM; POTASSIUM CHLORIDE 1.015GM; SODIUM ASCORBATE 5.9GM; SODIUM CHLORIDE 2.691GM; SODIUM SULFATE 7.5GM · FOR SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Ascorbic Acid" as an intervention, any sponsor and status, largest first.

All 617 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting334
  • nausea264
  • drug ineffective231
  • diarrhoea144
  • abdominal pain140
  • hyponatraemia121
  • pyrexia120
  • headache118
  • dehydration112
  • dyspnoea112
  • malaise105
  • pain91

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
200714
200820
200946
201040
2011351
2012289
201336
201459
2015201
2016209
2017186
2018169
2019173
2020124
2021107
2022101
202358
202453
202551
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Moviprep (PEG3350/Sod Sul/NaCl/KCl/Asb/C)

2024 spending

$48K

Beneficiaries

360

375 claims

Per beneficiary

$135

$115.99 per unit

View as table
YearSpending
2020$991,490
2021$458,692
2022$131,194
2023$73,171
2024$48,426

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,317 on PubMed

Sponsor: Salix Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.